<DOC>
	<DOC>NCT02770625</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease.</brief_summary>
	<brief_title>Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Diagnosis of Type 1 GD. Documented glucocerebrosidase deficiency. GDrelated anemia, defined as hemoglobin levels of at least 1 g/dL below the lower limit of normal for age and gender and one or more of the following 3 criteria: At least moderate splenomegaly (2 to 3 cm below the left costal margin) by palpation, GDrelated thrombocytopenia, defined as a platelet count &lt;90 x 109 platelets/L, GDrelated readily palpable enlarged liver. Not received treatment for GD (investigational products, miglustat, velaglucerase alfa, or imiglucerase) within 12 months prior to study entry. Ability to comprehend and willing to sign the ICF. Legal guardian (and patient if age appropriate) understood the nature of the procedure, was willing to comply with associated followup evaluations, and provided written informed consent and assent prior to the procedure. Female patients of childbearing potential must had agreed to use a medically acceptable method of contraception at all the times during the study. Male patients must have used a medically acceptable method of birth control throughout their participation in the study and were required to report the pregnancy of a partner. Type 2 or 3 GD. Splenectomy. Antibody positive to ISU302 or imiglucerase during screening or the patient had experienced an anaphylactic reaction to ISU302 or imiglucerase. Treatment with any nonGDrelated investigational drug or medical device within 30 days prior to study entry; such use during the study was also not permitted. Currently receiving red blood cell (RBC) growth factor (eg, erythropoietin) chronic systemic corticosteroids or received such treatment within the last 6 months. Positive for human immunodeficiency virus (HIV) and hepatitis B or C. Exacerbated anemia at screening (due to iron, folic acid, or vitamin B12 deficiency or infectious/immunemediated cause). Significant comorbidity(ies) that could affect study data or confounded the study results (eg, malignancies, primary biliary cirrhosis, autoimmune liver disease). Pregnant or lactating female patients and those not willing to use highly effective barrier or medical method of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type I Gaucher</keyword>
	<keyword>ISU302</keyword>
	<keyword>Imiglucerase</keyword>
</DOC>